Table 4.
Hazards of death from the onset of systemic therapy.
| Dependent: Hazards of death | all | Total | HR (CPH univariable) | HR (CPH multivariable) | |
|---|---|---|---|---|---|
| Age > 60 at initiation of systemic therapy | No | 152 (42.6) | 152 (42.6) | - | - |
| Yes | 205 (57.4) | 205 (57.4) | 0.95 (0.75–1.19, p = 0.660) | 0.89 (0.71–1.12, p = 0.317) | |
| Nephrectomy prior to systemic therapy | Yes | 153 (42.9) | 153 (42.9) | - | - |
| No | 204 (57.1) | 204 (57.1) | 1.73 (1.37–2.19, p < 0.001) | 1.53 (1.20–1.96, p = 0.001) | |
| Sex | Male | 227 (63.6) | 227 (63.6) | - | - |
| Female | 130 (36.4) | 130 (36.4) | 1.13 (0.89–1.43, p = 0.311) | 1.14 (0.90–1.44, p = 0.273) | |
| 40% eGFR decline within 1 year of systemic therapy | No | 275 (77.0) | 275 (77.0) | - | - |
| Yes | 82 (23.0) | 82 (23.0) | 1.06 (0.81–1.39, p = 0.676) | 1.11 (0.85–1.46, p = 0.443) | |
| Metastatic cancer | No | 238 (66.7) | 238 (66.7) | - | - |
| Yes | 119 (33.3) | 119 (33.3) | 1.84 (1.45–2.33, p < 0.001) | 1.62 (1.26–2.08, p < 0.001) |
This is demonstrated as univariable, multivariable cox proportional hazards (CPH) for death. Multivariable adjustment for all the included covariates.